● Recruiting

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Condition: Triple Negative Breast Cancer · Sponsor: West China Hospital

PhasePhase 2

Planned participants35

Who can joinFemale, 18 Years to 75 Years

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).

This description comes directly from the study's public registry record.

Talk to the study team

Ting Luo, MD · +86 18602866299 · tina621@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05447702